Dr. Adrienne Block has been working with GlyGenix Therapeutics since it was founded in 2006.. She is also a founding member of The UCAN Company.. Prior to the Bayer Healthcare restructuring in 2008, Dr Block was the Director of Scientific Communications in both the Hemotology/Cardiology and the Oncology Groups. With a budget of over $3. Million, Dr. Block supervised communication strategies, publications and developed marketing and sales objectives for Trasylol, Kogenate FS and Nexavar.. The previous 15 years, also at Bayer, she held Manager, Associate Director and Deputy Director positions.. Dr Block graduated from SUNY Albany with concentrations in Biology and Chemistry. At SUNY Buffalo she obtained a B.S. in Pharmacy, and then completed her PhD in Pharmacology at Northwestern University Medical School.
